LEGN Legend Biotech
- 57.540
- +0.690+1.21%
Legend Biotech News
Legend Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Legend Biotech Announces Positive Overall Survival in CARTITUDE-4 Phase 3 Trial
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 6-K: Legend Biotech Announced Results for the First Time from the Phase 2 CARTITUDE-2 Cohort D Study in Multiple Myeloma Patients
Legend Biotech | 6-K: Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
Legend Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(3.0%)
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Legend Biotech | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Analysis
Price Target
No Data
